Cardiology

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

Published on October 13, the latest scientific statement from the American Heart Association highlights the current role of patient-reported outcome measures in the management of peripheral artery disease as well as future considerations for optimizing this role and benefits in care.

An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

The beneficial effect of intensive BP control on cardiovascular and all-cause mortality was attenuated during 4.5 years of post-trial after SPRINT.

A systematic review and meta-analysis with data from more than 55 million individuals is providing new insight into the relative risk of myocarditis following a COVID-19 infection compared with vaccination.

Paxlovid is effective in patients with existing heart disease, but has significant DDIs with commonly used cardiovascular medications.

Mobile health technology to detect AF led to a high rate of false positives in patients with certain cardiac conditions.

Sotatercept added to background therapy demonstrated significant improvement in exercise capacity compared to placebo.

The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.

Our latest cardiology case report features a patient in their mid-70’s presenting to the hospital with reports of feeling sluggish and a heart rate in the 40s. Check out the EKG and determine the correct diagnosis.

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

The observed reductions in CV mortality in patients treated with dapagliflozin were primarily due to lower rates of HF and sudden death.

Martin Maron, MD, sits down to discuss aficamten, the SEQUOIA-HCM trial, and the most pressing unmet needs in the management of hypertrophic cardiomyopathy.

Martha Gulati, MD, joins The Heart Team to share her professional experiences and recommendations in treating female-specific cardiovascular disease.

Martha Gulati, MD, joins episode 2 to discuss the burden of gender disparity in cardiovascular research, screening and care.

Data presented at HFSA 2022 examining aficamten provides insight into the effects of the agent on LVOT-G, NYHA class, and KCCQ-OSS among patients with hypertrophic cardiomyopathy from the open-label extension trial.

Martin Maron, MD, provides perspective on a recent study he led examining changes in rate of sudden cardiac death among patients with hypertrophic cardiomyopathy and reflects on the progress made within disease management.

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

A University of Michigan-led analysis of NHANES data provides insight into the increases in prevalence of food insecurity among patients with cardiovascular disease in the US across racial and ethnic groups.

NAFLD resulted in a number of other negative outcomes, including sleep disturbance, cardiovascular disease, significant hepatic fibrosis, and advanced hepatic fibrosis.

Research finds potential benefits to using apremilast for plaque psoriasis patients.

"Collectively, this work highlights and supports chronotype as a potential risk factor related to type 2 diabetes and cardiovascular disease risk," investigators wrote.